News | Proton Therapy | February 10, 2020

Global Radiation Therapy Market to Reach $8.6B by 2026

Growing prevalence of cancer behind high demand for radiation therapy, but high costs to restraint market from reaching full potential

The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

February 10, 2020 — Amid technological advancement, and notable research and development activities, the global radiation therapy market is set to chart a sturdy growth curve, owing to a steady growth rate of 5.2 percent from 2018 to 2026, according to a newly released report. As per Transparency Market Research (TMR), the growth is attributable to surge in product approvals, increase in expenditure on healthcare, high incidence of cancer, and a growing preference for non-invasive treatment procedures.

TMR states that, "From bench to clinic, there is a wave of therapeutic and diagnostic technologies, paving way for higher growth in oncology. And, this will aid radiation therapy witness better times to come. Over the forecast period external beam radiation therapy will dominate the market landscape."

Key Findings of the Radiation Therapy Market Study

  • Hospitals to dominate the end-user segment over the forecast period owing to robust infrastructure with state of the art-equipment and services usually available
  • External beam radiation therapy demand to account for a huge share owing to a stream of notable approvals and significant advancement in technology
  • Emerging economies to witness increase in need for radiation therapy owing to increase in incidence of cancer and growing awareness regarding the same; India and China to dominate regional demand curve

Radiation Therapy Market: Key Driving Factors

The market report, based on extensive research by Transparency Market Research, is leading to growth in the landscape. And, a wave of innovation is keeping the statistics buoyant over the period. Some of the factors that will sustain growth over the forecast period in the global radiation therapy market include the following:

  • Every year 439.2 people out of 100,000 add to the already huge pool of cancer patients worldwide and out of these 163.5 die each year
  • In United States alone, in 2018, 609,640 will die out of 1,735,350 people diagnosed with cancer
  • Approvals for products such as MRIdian Linac system, created by ViewRay, Inc., in 2017 is aiding the market chart high growth over the forecast period
  • Owing to high contribution from the United States of America, which is a large market of radiation therapy, North American region will dominate market landscape

Key Impediments for Radiation Therapy Market Players

While the overall outlook of the global radiation therapy market is positive, TMR speaks of certain restraints that will hamper growth to some extent. According to the study, the key restraints impeding market growth include,

  • High cost of treatment – unaffordable for a large chunk of people in the developing region, particularly in countries where healthcare cover is particularly low
  • Low awareness levels – Patients sometime are not aware of cancer cells wreaking havoc in the body till too late, this leads to late diagnosis
  • Radiation takes a toll on the body and the side effects make it difficult to tolerate for some patients

Radiation Therapy Market: Region-wise Analysis

  • One of the biggest revenue generators in the global radiation therapy market is the Asia Pacific region with Japan, China, and India, leading the way, credit rising levels of disposable income, and improving healthcare infrastructure
  • In countries such as India, expenses towards healthcare are increased and an effort to provide insurance cover to more and more people is set to contribute positively to regional growth
  • Large patient pool in the region and increasing awareness related to cancer symptoms and diagnosis is also a positive factor, promising to help the region chart significant growth  

Competitive Landscape

Strategic alliances and a keen focus on technological advancement is the key to growth for players operating in the global radiation therapy market over the forecast period. One of the most notable agreement that took place in the recent past – November 2018 – is that between Chengdu Xingcheng and Mevion. The aim behind the move is to lead center for proton therapy in China's sub-provincial city – Chengdu.

Besides, players are focused on product development and launch. For instance, in the year 2018, ProBeam 360 – a system of single room proton therapy - was launched by Varian Medical Systems. In the same year Hitachi Ltd. received approval for commercialization of RGPT.

Key players include Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc. (US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt. Ltd. (India), Provision Healthcare (US), and Mevion Medical Systems, Inc. (US)

By Type:

External beam Radiation Therapy

  • Conformal Radiation Therapy
  • Proton Beam Therapy
  • Image Guided Radiation Therapy
  • Stereotactic Radiation Therapy

Internal Radiation Therapy

  • Brachytherapy
  • Systemic Radiation Therapy

By End user:

  • Hospitals
  • Specialty Clinics

For more information: www.transparencymarketresearch.com

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...